Glanbia says it is increasing its full-year earnings forecast after reporting a strong first half and citing continued momentum in protein demand. Multiple outlets report that the company now expects higher-than-expected revenue growth across its nutrition divisions. One report links the demand trends partly to the broader market for weight-loss drugs, which is associated with increased interest in protein products, although Glanbia’s commentary is framed within wider protein consumption trends rather than a single driver.
All sources agree that Glanbia’s upgraded outlook follows improved trading performance in the first six months. The company’s revisions reflect expectations that demand will remain solid for its nutrition offerings, supporting both revenue and earnings outlooks for the year. The reports do not provide detailed financial figures or specific percentage changes, but they consistently describe the update as a forecast “bulk up” driven by stronger-than-expected performance and sustained protein product demand.
